Amyloid-β42 plasma levels are elevated in amnestic mild cognitive impairment

Sergio Cammarata, Roberta Borghi, Luca Giliberto, Matteo Pardini, Valeria Pollero, Cristina Novello, Michele Fornaro, Antonella Vitali, Laura Bracco, Carlo Caltagirone, Paola Bossù, Patrizio Odetti, Massimo Tabaton

Research output: Contribution to journalArticlepeer-review


Amnestic mild cognitive impairment (aMCI) is considered a prodromal stage of Alzheimer's disease (AD). We measured plasma levels of amyloid-β-{40} (Aβ-{40}) and Aβ-{42} in 191 subjects with aMCI. Seventy-nine of them were clinically followed for two years. In the total cohort of aMCI cases, the average level of Aβ-{42}, as well as the Aβ-{42}/Aβ-{40} ratio, was significantly higher than those of the 102 cognitively normal age-matched subjects. The aMCI cases that converted to probable AD within 2 years had higher levels of Aβ-{42} and, to a lesser extent, Aβ-{40} than the stable cases. However the large variability of measured values indicates that plasma Aβ is not a suitable marker of incipient AD.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalJournal of Alzheimer's Disease
Issue number2
Publication statusPublished - 2009


  • Alzheimer's disease
  • Amyloid-β
  • Mild cognitive impairment
  • Plasma

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology
  • Medicine(all)


Dive into the research topics of 'Amyloid-β42 plasma levels are elevated in amnestic mild cognitive impairment'. Together they form a unique fingerprint.

Cite this